Alaska Permanent Fund’s GSK GSK Stock Holding History

Alaska Permanent Fund’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,759	Closed	-$269K	–	186
2025 Q1	$269K	Hold	6,759	–	–	﹤0.01%	412
2024 Q4	$229K	Hold	6,759	–	–	﹤0.01%	420
2024 Q3	$276K	Hold	6,759	–	–	﹤0.01%	418
2024 Q2	$262K	Buy	6,759 +290	+4%	+$12.2K	﹤0.01%	417
2024 Q1	$277K	Buy	+6,469	New	+$267K	﹤0.01%	435

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Alaska Permanent Fund's GSK Position: Q2 2025 in Review

Alaska Permanent Fund sold out of GSK (GSK) in Q2 2025, closing a stake of 6,759 shares — an estimated $269K sold.

Alaska Permanent Fund first reported a position in GSK in Q1 2024 and held it in 5 quarters. The position peaked at $277K in Q1 2024. 890 funds tracked by Wall St. Rank hold GSK as of Q2 2025.

Alaska Permanent Fund reported no remaining GSK position as of Q2 2025 after selling out during the quarter.
Alaska Permanent Fund sold 6,759 GSK shares in Q2 2025, an estimated $269K.
Alaska Permanent Fund first reported a position in GSK in Q1 2024 and held it in 5 quarters.
Alaska Permanent Fund's GSK position peaked at $277K in Q1 2024.
890 funds tracked by Wall St. Rank held GSK as of Q2 2025.

Based on Alaska Permanent Fund's 13F filing for Q2 2025, filed 14 Aug 2025.